Letter From The Editor: Important Information On PharmAsia News
This article was originally published in PharmAsia News
PharmAsia News will cease publication as a stand-alone product at the end of June/early July. However, the on-the-ground team of journalists who produce PAN will all continue to provide the same in-depth insight, news, and analysis as previously, and this content will be made available through Informa’s updated Scrip platform. All PAN subscribers will receive Scrip from early July, and Asia-Pacific regulatory content will be available through the expanded Pink Sheet and its new platform.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.